

Supplementary Table 6. League matrix table for targets on different outcomes

Note: ACC, acetyl-coenzyme A carboxylase; CINeMA, Confidence in Network Meta-Analysis; FGF, fibroblast growth factor; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; GCG, glucagon; GIP, glucose-dependent insulintropic polypeptide; PPAR, peroxisome proliferator-activated receptor; THR, thyroid hormone receptor; RA, receptor agonist.

Supplementary Table 6.1. Fibrosis improvement ≥ 1 stage without steatohepatitis worsening

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as odds ratio and 95% confidence interval (CI). For instance, the odds ratio in fibrosis improvement at least one stage without steatohepatitis worsening for FGF21 analogue compared to GLP-1 RA is 1.75 (95%CI: 0.84 to 3.63). § as very low, * as low, † as moderate, and ★ as high confidence in the evidence. The certainty of evidence was assessed by CINeMA.

FGF21 analogue										
1.61 (0.56, 4.60) [†]	FGF19 analogue									
0.74 (0.16, 3.38) [†]	0.46 (0.09, 2.26) [§]	d-(R)- Pioglitazone								
1.20 (0.50, 2.88) [§]	0.74 (0.27, 2.01) [†]	1.61 (0.37, 7.09) [§]	PPAR agonist							
1.75 (0.84, 3.63) [†]	1.09 (0.45, 2.59) [†]	2.36 (0.58, 9.54) [§]	1.46 (0.76, 2.81) [†]	GLP-1 RA						
1.72 (0.82, 3.64) [†]	1.07 (0.44, 2.59) [†]	2.33 (0.57, 9.49) [§]	1.44 (0.74, 2.82) [†]	0.99 (0.62, 1.56) [†]	THR-β agonist					
1.30 (0.58, 2.93) [†]	0.81 (0.32, 2.06) [†]	1.76 (0.42, 7.42) [§]	0.86 (0.32, 2.31) [†]	0.75 (0.43, 1.30) [†]	0.76 (0.43, 1.34) [†]	FXR agonist				
1.03 (0.37, 2.92) [†]	0.64 (0.21, 2.01) [†]	1.40 (0.29, 6.77) [§]	0.86 (0.32, 2.31) [†]	0.59 (0.25, 1.39) [†]	0.60 (0.25, 1.43) [†]	0.79 (0.32, 2.00) [†]	GLP-1/GCG dual RA			
1.17 (0.40, 3.44) [†]	0.73 (0.22, 2.36) [†]	1.58 (0.32, 7.87) [§]	0.98 (0.35, 2.73) [†]	0.67 (0.27, 1.65) [†]	0.68 (0.27, 1.69) [†]	0.90 (0.34, 2.36) [†]	1.13 (0.35, 3.63) [†]	GLP-1/GIP dual RA		
3.52 (1.81, 6.85) [★]	2.19 (0.97, 4.94) [†]	4.75 (1.21, 18.58) [§]	2.94 (1.66, 5.24) [★]	2.02 (1.48, 2.74) [★]	2.04 (1.45, 2.87) [★]	2.70 (1.70, 4.29) [★]	3.40 (1.53, 7.56) [★]	3.01 (1.29, 7.02) [★]	Placebo	

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as odds ratio and 95% confidence interval (CI). For instance, the odds ratio in fibrosis improvement at least one stage without steatohepatitis worsening for FGF21 analogue compared to GLP-1 RA is 0.89 (95%CI: 0.26 to 2.99). § as very low, * as low, † as moderate, and ★ as high confidence in the evidence. The certainty of evidence was assessed by CINeMA.

FGF21 analogue									
1.06 (0.21, 5.42) [†]	FGF19 analogue								
2.89 (0.46, 18.12) [§]	2.73 (0.35, 21.05) [§]	d-(R)- Pioglitazone							
0.89 (0.26, 2.99) [†]	0.84 (0.19, 3.80) [†]	0.31 (0.05, 1.73) [§]	GLP-1RA						
1.14 (0.34, 3.77) [†]	1.08 (0.24, 4.80) [†]	0.39 (0.07, 2.20) [§]	1.28 (0.46, 3.59) [†]	THR-β agonist					
1.31 (0.40, 4.28) [†]	1.23 (0.28, 5.46) [†]	0.45 (0.08, 2.50) [§]	1.47 (0.54, 3.98) [†]	1.15 (0.42, 3.10) [†]	PPAR agonist				
1.64 (0.46, 5.80) [*]	1.55 (0.33, 7.28) [†]	0.57 (0.10, 3.31) [§]	1.84 (0.61, 5.55) [†]	1.15 (0.42, 3.10) [†]	1.26 (0.43, 3.67) [†]	FXR agonist			
0.38 (0.08, 1.84) [†]	0.36 (0.06, 2.20) [†]	0.13 (0.02, 0.97) [§]	0.43 (0.10, 1.82) [†]	0.33 (0.08, 1.40) [†]	0.29 (0.07, 1.21) [†]	0.23 (0.05, 1.03) [†]	GLP-1/GCG dual RA		
0.28 (0.05, 1.61) [†]	0.27 (0.04, 1.89) [†]	0.10 (0.01, 0.82) [§]	0.32 (0.06, 1.61) [†]	0.25 (0.05, 1.24) [†]	0.22 (0.04, 1.07) [†]	0.17 (0.03, 0.91) [†]	0.74 (0.11, 5.00) [†]	GLP-1/GIP dual RA	
4.06 (1.55, 10.65) [*]	3.84 (1.03, 14.31) [†]	1.41 (0.29, 6.71) [§]	4.57 (2.18, 9.55) [*]	3.56 (1.75, 7.24) [†]	3.11 (1.56, 6.22) [*]	2.48 (1.10, 5.60) [*]	10.67 (3.07, 37.04) [*]	14.33 (3.39, 60.57) [*]	Placebo

Supplementary Table 6.3. Relative change from baseline in liver fat content

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in relative change from baseline in liver fat content for FGF19 analogue compared to THR- β agonist is -1.67 (95%CI: -23.36 to 20.01). § as very low, * as low, † as moderate, and ★ as high confidence in the evidence. The certainty of evidence was assessed by CINeMA.

[illegible]

Supplementary Table 6.4. Absolute change from baseline in liver fat content

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in absolute change from baseline in liver fat content for GLP-1 RA compared to PPAR agonist is 1.60 (95%CI: -12.42 to 15.62). § as very low, * as low, † as moderate, and ★ as high confidence in the evidence. The certainty of evidence was assessed by CINeMA.

FGF21 analogue																				
-5.66 (-10.77, -0.56)*	FXR agonist																			
-3.05 (-8.75, 2.65)*	2.61 (-3.33, 8.55)*	FGF19 analogue																		
-6.55 (-14.14, 1.05) [§]	-0.88 (-8.65, 6.89) [§]	-3.49 (-11.67, 4.69) [§]	GLP-1 RA																	
-5.91 (-13.67, 1.86) [§]	-0.24 (-8.18, 7.70) [§]	-2.85 (-11.19, 5.49) [§]	0.64 (-9.09, 10.37) [§]	d-(R)-Pioglitazone																
-4.65 (-12.05, 2.76)*	1.02 (-6.56, 8.60)*	-1.59 (-9.60, 6.41)*	1.90 (-7.54, 11.34) [§]	1.26 (-8.32, 10.84) [§]	THR-β agonist															
-4.95 (-17.69, 7.80)*	0.72 (-12.12, 13.56)*	-1.89 (-14.99, 11.20)*	1.60 (-12.42, 15.62) [§]	0.96 (-13.15, 15.07) [§]	-0.30 (-14.22, 13.62)*	PPAR agonist														
4.45 (-8.90, 12.81)*	10.12 (1.61, 18.63)*	7.51 (-1.38, 16.39)*	11.00 (0.80, 21.20) [§]	10.36 (0.03, 20.69) [§]	9.10 (-0.96, 19.16)*	9.40 (-5.04, 23.84)*	GLP-1/GCG dual RA													
-4.55 (-14.63, 5.54) [§]	1.12 (-9.10, 11.33) [§]	-1.49 (-12.03, 9.04) [§]	2.00 (-4.63, 8.63) [§]	1.36 (-10.41, 13.13) [§]	0.10 (-11.44, 11.64) [§]	0.40 (-15.11, 15.91) [§]	-9.00 (-21.17, 3.17) [§]	GLP-1 RA+ FXR agonist												
-3.55 (-13.63, 6.54) [§]	2.12 (-8.10, 12.33) [§]	-0.49 (-11.03, 10.04) [§]	3.00 (-3.63, 9.63) [§]	2.36 (-9.41, 14.13) [§]	1.10 (-10.44, 12.64) [§]	1.40 (-14.11, 16.91) [§]	-8.00 (-20.17, 4.17) [§]	1.00 (-5.62, 7.62) [§]	GLP-1 RA+ ACC inhibitor											
-3.55 (-13.67, 6.58) [§]	2.12 (-8.13, 12.37) [§]	-0.49 (-11.06, 10.07) [§]	3.00 (-3.69, 9.69) [§]	2.36 (-9.45, 14.17) [§]	1.10 (-10.47, 12.67) [§]	1.40 (-14.14, 16.94) [§]	-8.00 (-20.20, 4.20) [§]	1.00 (-5.67, 7.67) [§]	0.00 (-6.68, 6.68) [§]	GLP-1 RA+ ACC inhibitor+ FXR agonist										
-10.05 (-13.47, -6.62)*	-4.38 (-8.17, -0.59)*	-6.99 (-11.57, -2.42)*	-3.50 (-10.28, 3.28) [§]	-4.14 (-11.11, 2.83) [§]	-5.40 (-11.97, 1.17)*	-5.10 (-17.37, 7.17)*	-14.50 (-22.12, -6.88)*	-3.50 (-14.99, 3.99) [§]	-6.50 (-15.99, 2.99) [§]	-6.50 (-16.03, 3.03) [§]	Placebo									

Supplementary Table 6.5. Alanine aminotransferase (ALT)

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in ALT for FXR agonist compared to GLP-1 RA is 6.71 (95%CI: -6.92 to 20.34).

FGF21 analogue										
-11.38 (-23.52, 0.76)	FXR agonist									
5.46 (-8.93, 19.85)	16.84 (3.97, 29.71)	FGF19 analogue								
-4.68 (-19.67, 10.32)	6.71 (-6.92, 20.34)	-10.13 (-25.79, 5.52)	GLP-1 RA							
6.21 (-8.17, 20.59)	17.59 (4.76, 30.43)	0.75 (-14.25, 15.76)	10.89 (-4.77, 26.54)	PPAR agonist						
-17.49 (-33.86, -1.12)	-6.11 (-21.11, 8.90)	-22.95 (-39.85, -6.04)	-12.81 (-30.33, 4.70)	-23.70 (-40.58, -6.82)	d-(R)- Pioglitazone					
2.41 (-20.41, 25.24)	13.79 (-8.07, 35.66)	-3.05 (-26.26, 20.17)	7.09 (-16.57, 30.75)	-3.80 (-26.99, 19.39)	19.90 (-4.56, 44.36)	THR-β agonist				
-5.31 (-19.47, 8.85)	6.07 (-6.63, 18.78)	-10.77 (-25.62, 4.09)	-0.63 (-13.17, 11.91)	-11.52 (-26.37, 3.33)	12.18 (-4.63, 28.99)	-7.72 (-30.86, 15.42)	GLP-1/GCG dual RA			
14.32 (-9.12, 37.77)	25.71 (3.11, 48.31)	8.87 (-15.00, 32.74)	19.00 (0.98, 37.02)	8.11 (-15.76, 31.99)	31.81 (6.68, 56.95)	11.91 (-17.83, 41.66)	19.63 (-2.32, 41.59)	GLP-1 RA+FXR agonist		
19.32 (-4.29, 42.93)	30.71 (7.94, 53.47)	13.87 (-10.16, 37.90)	24.00 (5.76, 42.24)	13.11 (-10.92, 37.15)	36.81 (11.53, 62.10)	16.91 (-12.96, 46.79)	24.63 (2.50, 46.76)	5.00 (-12.24, 22.24)	GLP-1 RA+ACC inhibitor	
22.32 (-1.32, 45.97)	33.71 (10.91, 56.51)	16.87 (-7.20, 40.93)	27.00 (8.72, 45.28)	16.11 (-7.95, 40.18)	39.81 (14.50, 65.13)	19.91 (-9.99, 49.81)	27.63 (5.47, 49.80)	8.00 (-9.29, 25.29)	3.00 (-14.51, 20.51)	GLP-1 RA+ACC inhibitor +FXR agonist

Supplementary Table 6.6. Aspartate aminotransferase (AST)

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in AST for FXR agonist compared to GLP-1 RA is 9.97 (95%CI: -1.28 to 21.21).

FGF21 analogue										
-8.91 (-18.65, 0.83)	FXR agonist									
3.08 (-8.70, 14.86)	11.99 (1.29, 22.69)	FGF19 analogue								
1.06 (-11.22, 13.34)	9.97 (-1.28, 21.21)	-2.02 (-15.08, 11.03)	GLP-1 RA							
-3.05 (-17.02, 10.91)	5.86 (-7.20, 18.92)	-6.13 (-20.76, 8.50)	-4.11 (-19.18, 10.96)	PPAR agonist						
-11.49 (-33.25, 10.28)	-2.58 (-23.77, 18.62)	-14.57 (-36.77, 7.64)	-12.54 (-35.02, 9.94)	-8.44 (-31.86, 14.99)	d-(R)- Pioglitazone					
-3.49 (-18.55, 11.58)	5.42 (-8.81, 19.66)	-6.57 (-22.26, 9.13)	-4.54 (-20.62, 11.54)	-0.44 (-17.82, 16.94)	8.00 (-16.11, 32.11)	THR-β agonist				
6.64 (-7.57, 20.84)	15.55 (2.22, 28.88)	3.56 (-11.34, 18.46)	5.58 (-5.20, 16.37)	9.69 (-7.08, 26.45)	18.12 (-5.48, 41.73)	10.12 (-7.49, 27.74)	GLP-1/GCG dual RA			
11.06 (-9.19, 31.30)	19.97 (0.33, 39.60)	7.98 (-12.75, 28.70)	10.00 (-6.10, 26.10)	14.11 (-7.94, 36.16)	22.54 (-5.11, 50.19)	14.54 (-8.21, 37.30)	4.42 (-14.96, 23.80)	GLP-1 RA+FXR agonist		
16.06 (-4.39, 36.50)	24.97 (5.13, 44.81)	12.98 (-7.94, 33.90)	15.00 (-1.35, 31.35)	19.11 (-3.12, 41.34)	27.54 (-0.25, 55.34)	19.54 (-3.39, 42.47)	9.42 (-10.16, 29.00)	5.00 (-10.58, 20.58)	GLP-1 RA+ ACC inhibitor	
16.06 (-4.60, 36.71)	24.97 (4.91, 45.03)	12.98 (-8.15, 34.10)	15.00 (-1.61, 31.61)	19.11 (-3.32, 41.53)	27.54 (-0.41, 55.49)	19.54 (-3.57, 42.66)	9.42 (-10.38, 29.22)	5.00 (-10.85, 20.85)	0.00 (-16.11, 16.11)	GLP-1 RA+ACC inhibitor +FXR agonist

Supplementary Table 6.7. Body weight

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in body weight for FXR agonist compared to GLP-1 RA is 2.50 (95%CI: 0.77 to 4.22).

[illegible]

Supplementary Table 6.8. Triglyceride

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in triglyceride for FXR agonist compared to GLP-1 RA is 37.67 (95%CI: -5.25 to 80.60).

FGF21 analogue								
-42.04 (-69.50, -14.57)	FXR agonist							
-5.67 (-35.84, 24.50)	36.37 (8.15, 64.59)	FGF19 analogue						
-4.36 (-48.49, 39.76)	37.67 (-5.25, 80.60)	1.31 (-43.12, 45.74)	GLP-1 RA					
17.16 (-11.50, 45.82)	59.19 (32.64, 85.74)	22.83 (-6.37, 52.03)	21.52 (-21.92, 64.96)	PPAR agonist				
12.28 (-23.75, 48.32)	54.32 (19.96, 88.68)	17.95 (-18.52, 54.43)	16.65 (-31.99, 65.28)	-4.87 (-40.12, 30.37)	GLP-1/GCG dual RA			
10.64 (-53.62, 74.90)	52.67 (-10.76, 116.11)	16.31 (-48.16, 80.77)	15.00 (-31.71, 61.71)	-6.52 (-70.31, 57.27)	-1.65 (-69.08, 65.79)	GLP-1 RA+ FXR agonist		
-47.36 (-112.54, 17.82)	-5.33 (-69.70, 59.05)	-41.69 (-107.08, 23.70)	-43.00 (-90.98, 4.98)	-64.52 (-129.24, 0.20)	-59.65 (-127.97, 8.67)	-58.00 (-104.03, -11.97)	GLP-1 RA+ ACC inhibitor	
-58.36 (-124.27, 7.55)	-16.33 (-81.43, 48.78)	-52.69 (-118.81, 13.42)	-54.00 (-102.96, -5.04)	-75.52 (-140.97, -10.07)	-70.65 (-139.66, -1.63)	-69.00 (-116.05, -21.95)	-11.00 (-59.31, 37.31)	GLP-1 RA+ ACC inhibitor +FXR agonist

Supplementary Table 6.9. High density lipoprotein-cholesterol (LDL-C)

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in LDL-C for FXR agonist compared to GLP-1 RA is 28.19 (95%CI: -8.96 to 65.34).

FGF21 analogue								
-19.90 (-51.35, 11.55)	FXR agonist							
-28.53 (-60.19, 3.14)	-8.63 (-37.04, 19.79)	FGF19 analogue						
8.29 (-31.57, 48.14)	28.19 (-8.96, 65.34)	36.82 (-0.64, 74.27)	GLP-1 RA					
-18.66 (-50.35, 13.02)	1.24 (-27.18, 29.65)	9.86 (-18.82, 38.54)	-26.95 (-64.37, 10.46)	PPAR agonist				
-3.61 (-38.99, 31.77)	16.29 (-16.19, 48.76)	24.92 (-7.80, 57.63)	-11.90 (-52.46, 28.66)	15.05 (-17.67, 47.77)	GLP-1/GCG dual RA			
-0.71 (-55.13, 53.71)	19.19 (-33.28, 71.65)	27.82 (-24.87, 80.50)	-9.00 (-46.05, 28.05)	17.95 (-34.71, 70.61)	2.90 (-52.04, 57.84)	GLP-1 RA+ FXR agonist		
4.29 (-50.24, 58.81)	24.19 (-28.39, 76.77)	32.82 (-19.98, 85.61)	-4.00 (-41.21, 33.21)	22.95 (-29.82, 75.72)	7.90 (-47.14, 62.94)	5.00 (-31.71, 41.71)	GLP-1 RA+ ACC inhibitor	
-7.71 (-62.59, 47.16)	12.19 (-40.75, 65.13)	20.82 (-32.34, 73.97)	-16.00 (-53.72, 21.72)	10.95 (-42.18, 64.08)	-4.10 (-59.49, 51.29)	-7.00 (-44.23, 30.23)	-12.00 (-49.39, 25.39)	GLP-1 RA+ ACC inhibitor+ FXR agonist

Supplementary Table 6.10. High density lipoprotein-cholesterol (HDL-C)

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in HDL-C for FXR agonist compared to GLP-1 RA is -3.38 (95%CI: -11.10 to 4.34).

FGF21 analogue								
9.11 (3.02, 15.21)	FXR agonist							
6.38 (0.03, 12.74)	-2.73 (-8.76, 3.30)	FGF19 analogue						
5.74 (-2.24, 13.71)	-3.38 (-11.10, 4.34)	-0.65 (-8.58, 7.28)	GLP-1 RA					
3.61 (-2.58, 9.79)	-5.51 (-11.36, 0.35)	-2.78 (-8.90, 3.35)	-2.13 (-9.92, 5.66)	PPAR agonist				
6.09 (-0.59, 12.78)	-3.02 (-9.40, 3.36)	-0.29 (-6.92, 6.34)	0.36 (-7.84, 8.55)	2.49 (-3.98, 8.95)	GLP-1/GCG dual RA			
6.74 (-3.80, 17.27)	-2.38 (-12.72, 7.97)	0.35 (-10.15, 10.85)	1.00 (-5.88, 7.88)	3.13 (-7.26, 13.52)	0.64 (-10.06, 11.35)	GLP-1 RA+ FXR agonist		
9.74 (-0.90, 20.38)	0.62 (-9.83, 11.07)	3.35 (-7.25, 13.96)	4.00 (-3.04, 11.04)	6.13 (-4.37, 16.63)	3.64 (-7.16, 14.45)	3.00 (-3.88, 9.88)	GLP-1 RA+ ACC inhibitor	
9.74 (-1.03, 20.51)	0.62 (-9.96, 11.20)	3.35 (-7.38, 14.09)	4.00 (-3.24, 11.24)	6.13 (-4.50, 16.76)	3.64 (-7.29, 14.58)	3.00 (-4.08, 10.08)	0.00 (-7.24, 7.24)	GLP-1 RA+ ACC inhibitor+ FXR agonist

Supplementary Table 6.11. Total cholesterol

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in total cholesterol for FGF19 compared to GLP-1 RA is 30.71 (95%CI: -8.23 to 69.65).

FGF21 analogue									
-51.50 (-93.33, -9.68)	FXR agonist								
-43.83 (-83.07, -4.58)	7.68 (-23.19, 38.55)	FGF19 analogue							
-37.56 (-76.74, 1.61)	13.94 (-16.85, 44.73)	6.26 (-20.92, 33.44)	PPAR agonist						
-13.12 (-61.22, 34.99)	38.39 (-3.14, 79.92)	30.71 (-8.23, 69.65)	24.45 (-14.44, 63.33)	GLP-1 RA					
-17.12 (-59.40, 25.16)	34.38 (-0.26, 69.03)	26.71 (-4.78, 58.19)	20.44 (-10.96, 51.85)	-4.00 (-45.95, 37.94)	GLP-1/GCG dual RA				
-19.12 (-79.14, 40.91)	32.39 (-22.51, 87.28)	24.71 (-28.26, 77.68)	18.45 (-34.48, 71.37)	-6.00 (-41.90, 29.90)	-2.00 (-57.21, 53.22)	GLP-1 RA+ FXR agonist			
-21.12 (-81.35, 39.12)	30.39 (-24.73, 85.51)	22.71 (-30.49, 75.91)	16.45 (-36.71, 69.61)	-8.00 (-44.25, 28.25)	-4.00 (-59.43, 51.44)	-2.00 (-37.52, 33.52)	GLP-1 RA+ ACC inhibitor		
-31.12 (-91.35, 29.12)	20.39 (-34.73, 75.51)	12.71 (-40.49, 65.91)	6.45 (-46.71, 59.61)	-18.00 (-54.25, 18.25)	-14.00 (-69.43, 41.44)	-12.00 (-47.52, 23.52)	-10.00 (-45.88, 25.88)	GLP-1 RA+ ACC inhibitor+ FXR agonist	

Supplementary Table 6.12. Glycated hemoglobin (HbA1c)

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in HbA1c for FGF21 analogue compared to GLP-1 RA is 0.24 (95%CI: -0.52 to 1.01).

FGF21 analogue										
-0.31 (-0.96, 0.34)	FXR agonist									
-0.26 (-0.89, 0.36)	0.05 (-0.55, 0.65)	FGF19 analogue								
0.24 (-0.52, 1.01)	0.55 (-0.19, 1.30)	0.51 (-0.22, 1.23)	GLP-1 RA							
0.05 (-0.54, 0.63)	0.36 (-0.21, 0.92)	0.31 (-0.22, 0.84)	-0.20 (-0.89, 0.50)	PPAR agonist						
0.12 (-0.65, 0.89)	0.43 (-0.32, 1.17)	0.38 (-0.34, 1.10)	-0.12 (-0.97, 0.73)	0.07 (-0.62, 0.77)	d-(R)- Pioglitazone					
0.09 (-0.30, 0.82)	0.40 (-0.30, 1.11)	0.36 (-0.33, 1.04)	-0.15 (-0.97, 0.67)	0.05 (-0.60, 0.70)	-0.03 (-0.84, 0.79)	ACC inhibitor				
0.23 (-0.40, 0.86)	0.54 (-0.06, 1.15)	0.49 (-0.08, 1.07)	-0.01 (-0.74, 0.72)	0.19 (-0.35, 0.72)	0.11 (-0.62, 0.84)	0.14 (-0.55, 0.83)	GLP-1/GCG dual RA			
0.34 (-0.64, 1.33)	0.65 (-0.32, 1.62)	0.61 (-0.35, 1.56)	0.10 (-0.52, 0.72)	0.30 (-0.63, 1.23)	0.22 (-0.83, 1.28)	0.25 (-0.78, 1.28)	0.11 (-0.85, 1.07)	GLP-1 RA+ FXR agonist		
0.44 (-0.54, 1.43)	0.75 (-0.22, 1.72)	0.71 (-0.25, 1.66)	0.20 (-0.42, 0.82)	0.40 (-0.53, 1.33)	0.32 (-0.73, 1.38)	0.35 (-0.68, 1.38)	0.21 (-0.75, 1.17)	0.10 (-0.50, 0.70)	GLP-1 RA+ ACC inhibitor	
0.24 (-0.74, 1.23)	0.55 (-0.42, 1.52)	0.51 (-0.45, 1.46)	0.00 (-0.62, 0.62)	0.20 (-0.73, 1.13)	0.12 (-0.93, 1.18)	0.15 (-0.88, 1.18)	0.01 (-0.95, 0.97)	-0.10 (-0.70, 0.50)	-0.20 (-0.80, 0.40)	GLP-1 RA+ ACC inhibitor/ FXR agonist

Supplementary Table 6.13. Fasting blood glucose

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in fasting blood glucose for GLP-1 RA compared to FGF21 analogue is -4.22 (95%CI: -39.53 to 31.08).

FXR agonist								
-0.92 (-15.86, 14.03)	FGF19 analogue							
27.87 (12.81, 42.93)	28.79 (11.77, 45.80)	GLP-1 RA						
25.80 (10.91, 40.69)	26.72 (9.86, 43.58)	-2.07 (-19.03, 14.90)	PPAR agonist					
23.64 (-10.71, 58.00)	24.56 (-10.69, 59.82)	-4.22 (-39.53, 31.08)	-2.16 (-37.38, 33.07)	FGF21 analogue				
4.28 (-25.15, 33.72)	5.20 (-25.28, 35.68)	-23.58 (-54.12, 6.95)	-21.52 (-51.97, 8.93)	-19.36 (-62.78, 24.06)	GLP-1/GCG dual RA			
18.87 (-0.19, 37.92)	19.79 (-0.85, 40.42)	-9.00 (-20.67, 2.67)	-6.93 (-27.52, 13.66)	-4.78 (-41.96, 32.41)	14.58 (-18.11, 47.28)	GLP-1 RA+ FXR agonist		
28.87 (9.60, 48.14)	29.79 (8.95, 50.62)	1.00 (-11.02, 13.02)	3.07 (-17.72, 23.86)	5.22 (-32.07, 42.52)	24.58 (-8.23, 57.40)	10.00 (-1.67, 21.67)	GLP-1 RA+ ACC inhibitor	
19.87 (0.60, 39.14)	20.79 (-0.05, 41.62)	-8.00 (-20.02, 4.02)	-5.93 (-26.72, 14.86)	-3.78 (-41.07, 33.52)	15.58 (-17.23, 48.40)	1.00 (-10.67, 12.67)	-9.00 (-21.02, 3.02)	GLP-1 RA+ ACC inhibitor+ FXR agonist

Supplementary Table 6.14. Enhanced liver fibrosis (ELF) score

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in ELF score for FGF19 analogue compared to GLP-1 RA is 0.12 (95%CI: -0.40 to 0.63).

FGF21 analogue											
-0.34 (-0.65, -0.03)	FXR agonist										
-0.23 (-0.56, 0.09)	0.11 (-0.17, 0.38)	FGF19 analogue									
-0.22 (-0.71, 0.27)	0.12 (-0.34, 0.58)	0.01 (-0.46, 0.49)	d-(R)- Pioglitazone								
-0.25 (-0.60, 0.10)	0.09 (-0.21, 0.40)	-0.01 (-0.34, 0.31)	-0.03 (-0.52, 0.46)	PPAR agonist							
-0.12 (-0.65, 0.42)	0.22 (-0.28, 0.73)	0.12 (-0.40, 0.63)	0.10 (-0.53, 0.74)	0.13 (-0.40, 0.66)	GLP-1 RA						
-0.23 (-0.82, 0.37)	0.12 (-0.45, 0.68)	0.01 (-0.57, 0.59)	-0.01 (-0.69, 0.68)	0.02 (-0.57, 0.62)	-0.11 (-0.44, 0.23)	GLP-1/GCG dual RA					
0.16 (-0.31, 0.63)	0.50 (-0.06, 0.94)	0.39 (-0.06, 0.85)	0.38 (-0.20, 0.96)	0.41 (-0.06, 0.88)	0.28 (-0.34, 0.90)	0.39 (-0.29, 1.06)	GLP-1/GLP dual RA				
-0.21 (-0.92, 0.50)	0.13 (-0.55, 0.82)	0.03 (-0.67, 0.72)	0.01 (-0.77, 0.80)	0.04 (-0.67, 0.75)	-0.09 (-0.56, 0.38)	0.02 (-0.56, 0.59)	-0.37 (-1.14, 0.41)	GLP-1 RA+ FXR agonist			
-0.09 (-0.80, 0.62)	0.25 (-0.43, 0.94)	0.15 (-0.55, 0.84)	0.13 (-0.65, 0.92)	0.16 (-0.55, 0.87)	0.03 (-0.44, 0.50)	0.14 (-0.44, 0.71)	-0.25 (-1.02, 0.53)	0.12 (-0.34, 0.58)	GLP-1 RA+ ACC inhibitor		
-0.26 (-0.97, 0.45)	0.08 (-0.60, 0.77)	-0.02 (-0.72, 0.67)	-0.04 (-0.82, 0.75)	-0.01 (-0.72, 0.70)	-0.14 (-0.61, 0.33)	-0.03 (-0.61, 0.54)	-0.42 (-1.19, 0.36)	-0.05 (-0.51, 0.41)	-0.17 (-0.63, 0.29)	GLP-1 RA+ ACC inhibitor+ FXR agonist	

Supplementary Table 6.15. N-terminal type III collagen propeptide (PRO-C3)

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in PRO-C3 for FXR agonist compared to GLP-1 RA is 9.03 (95%CI: -2.64 to 20.70).

FGF21 analogue							
-6.87 (-12.98, -0.76)	FXR agonist						
-3.06 (-8.76, 2.64)	3.81 (-1.22, 8.85)	FGF19 analogue					
-5.63 (-12.82, 1.56)	1.24 (-5.42, 7.91)	-2.57 (-9.09, 3.95)	d-(R)- Pioglitazone				
-4.21 (-11.10, 2.68)	2.66 (-3.67, 9.00)	-1.15 (-7.33, 5.03)	1.42 (-6.15, 8.99)	PPAR agonist			
-1.24 (-9.18, 6.69)	5.63 (-2.35, 13.61)	1.82 (-5.81, 9.45)	4.39 (-4.41, 13.19)	2.97 (-5.59, 11.52)	GLP-1/GCG dual RA		
43.77 (24.55, 62.99)	50.64 (31.61, 69.67)	46.83 (27.85, 65.80)	49.40 (29.93, 68.87)	47.98 (28.62, 67.34)	45.01 (25.14, 64.89)	GLP-1/GIP dual RA	
2.16 (-9.48, 13.79)	9.03 (-2.64, 20.70)	5.22 (-6.21, 16.65)	7.79 (-4.46, 20.03)	6.37 (-5.70, 18.44)	3.40 (-5.11, 11.91)	-41.61 (-63.24, -19.99)	GLP-1 RA

Supplementary Table 6.16. Liver stiffness measurement assessed by vibration controlled transient elastography

Note: The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as mean difference and 95% confidence interval (CI). For instance, the mean difference in LSM-VCTE for GLP-1 RA compared to FXR agonist is -0.41 (95%CI: -3.33 to 2.51).

FGF21 analogue				
-2.59 (-5.36, 0.18)	GLP-1 RA			
-3.00 (-6.27, 0.27)	-0.41 (-3.33, 2.51)	FXR agonist		
-0.42 (-3.28, 2.44)	2.17 (-0.28, 4.62)	2.58 (-0.43, 5.59)	GLP-1/GIP dual RA	
-3.04 (-5.41, -0.66)	-0.45 (-2.30, 1.41)	-0.04 (-2.59, 2.52)	-2.62 (-4.61, -0.62)	PPAR agonist